Lynne Krohn

Lynne Krohn

Auto-generated profile, based on publicly available information

Lynne Krohn

The Neuro (Montreal Neurological Institute-Hospital), McGill University

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2019 in Brain
Verified
Journal Article
Closed access
PDF file
CBCornelis Blauwendraat
Cornelis Blauwendraat
XRXylena Reed
Xylena Reed
LKLynne Krohn
Lynne Krohn
KHKarl Heilbron
Karl Heilbron
SBSara Bandres-Ciga
Sara Bandres-Ciga
ASAndrew B Singleton
Andrew B Singleton
Parkinson’s disease is a genetically complex disorder. Multiple genes have been shown to contribute to the risk of Parkinson’s disease, and currently 90 independent risk variants have been identified by genome-wide association studies. Thus far, a number of genes (including SNCA, LRRK2, and GBA) have been shown to contain variability across a spectrum of frequency and effect, from rare, highly penetrant variants to common risk alleles with small effect sizes. Variants in GBA, encoding the enzyme glucocerebrosidase, are associated with Lewy body diseases such as Parkinson’s disease and Lewy body dementia. These variants, which reduce or abolish enzymatic activity, confer a spectrum of disease risk, from 1.4- to >10-fold. An outstanding question in the field is what other genetic factors that influence GBA-associated risk for disease, and whether these overlap with known Parkinson’s disease risk variants. Using multiple, large case-control datasets, totalling 217 165 individuals (22 757 Parkinson’s disease cases, 13 431 Parkinson’s disease proxy cases, 622 Lewy body dementia cases and 180 355 controls), we identified 1691 Parkinson’s disease cases, 81 Lewy body dementia cases, 711 proxy cases and 7624 controls with a GBA variant (p.E326K, p.T369M or p.N370S). We performed a genome-wide association study and analysed the most recent Parkinson’s disease-associated genetic risk score to detect genetic influences on GBA risk and age at onset. We attempted to replicate our findings in two independent datasets, including the personal genetics company 23andMe, Inc. and whole-genome sequencing data. Our analysis showed that the overall Parkinson’s disease genetic risk score modifies risk for disease and decreases age at onset in carriers of GBA variants. Notably, this effect was consistent across all tested GBA risk variants. Dissecting this signal demonstrated that variants in close proximity to SNCA and CTSB (encoding cathepsin B) are the most significant contributors. Risk variants in the CTSB locus were identified to decrease mRNA expression of CTSB. Additional analyses suggest a possible genetic interaction between GBA and CTSB and GBA p.N370S induced pluripotent cell-derived neurons were shown to have decreased cathepsin B expression compared to controls. These data provide a genetic basis for modification of GBA-associated Parkinson’s disease risk and age at onset, although the total contribution of common genetics variants is not large. We further demonstrate that common variability at genes implicated in lysosomal function exerts the largest effect on GBA associated risk for disease. Further, these results have implications for selection of GBA carriers for therapeutic interventions.

28 October 2019 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
LKLynne Krohn
Lynne Krohn
TOTugba N Ozturk
Tugba N Ozturk
BVBenoît Vanderperre
Benoît Vanderperre
BBBouchra Ouled Amar Bencheikh
Bouchra Ouled Amar Bencheikh
JRJennifer A. Ruskey
Jennifer A. Ruskey
ZGZiv Gan‐Or
Ziv Gan‐Or

21 September 2021 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
EYEric Yu
Eric Yu
Aditya AmbatiAditya Ambati
Aditya Ambati
MAMaren Stolp Andersen
Maren Stolp Andersen
LKLynne Krohn
Lynne Krohn
MEMehrdad A. Estiar
Mehrdad A. Estiar
ZGZiv Gan-Or
Ziv Gan-Or
We fine mapped the leukocyte antigen (HLA)region in 13,770 Parkinson’s disease (PD) patients, 20,214 proxy-cases, and 490,861 controls of European origin. FourHLAtypes were associated with PD after correction for multiple comparisons,HLA-DQA1*03:01,HLA-DQB1*03:02,HLA-DRB1*04:01, andHLA-DRB1*04:04. Haplotype analyses followed by amino acid analysis and conditional analyses suggested that the association is protective and primarily driven by three specific amino acid polymorphisms present in mostHLA-DRB1*04 subtypes—11V, 13H, and 33H (OR = 0.87, 95% CI: 0.83–0.90,p < 8.23 × 10−9for all three variants). No other effects were present after adjustment for these amino acids. Our results suggest that specificHLA-DRB1variants are associated with reduced risk of PD, providing additional evidence for the role of the immune system in PD. Although effect size is small and has no diagnostic significance, understanding the mechanism underlying this association may lead to the identification of new targets for therapeutics development.

25 August 2020 in Neurology
Verified
Journal Article
Open access
PDF file
LKLynne Krohn
Lynne Krohn
JRJennifer A. Ruskey
Jennifer A. Ruskey
URUladzislau Rudakou
Uladzislau Rudakou
ELEtienne Leveille
Etienne Leveille
FAFarnaz Asayesh
Farnaz Asayesh
ZGZiv Gan-Or
Ziv Gan-Or
Objective To study the role of GBA variants in the risk for isolated REM sleep behavior disorder (iRBD) and conversion to overt neurodegeneration. Methods A total of 4,147 individuals were included: 1,061 patients with iRBD and 3,086 controls. GBA was fully sequenced using molecular inversion probes and Sanger sequencing. We analyzed the effects of GBA variants on the risk of iRBD, age at onset (AAO), and conversion rates. Results GBA variants were found in 9.5% of patients with iRBD compared to 4.1% of controls (odds ratio, 2.45; 95% confidence interval [CI], 1.87–3.22; p = 1 × 10−10). The estimated OR for mild p.N370S variant carriers was 3.69 (95% CI, 1.90–7.14; p = 3.5 × 10−5), while for severe variant carriers it was 17.55 (95% CI, 2.11–145.9; p = 0.0015). Carriers of severe GBA variants had an average AAO of 52.8 years, 7–8 years earlier than those with mild variants or noncarriers (p = 0.029). Of the GBA variant carriers with available data, 52.5% had converted, compared to 35.6% of noncarriers (p = 0.011), with a trend for faster conversion among severe GBA variant carriers. However, the results on AAO and conversion were based on small numbers and should be interpreted with caution. Conclusions GBA variants robustly and differentially increase the risk of iRBD. The rate of conversion to neurodegeneration is also increased and may be faster among severe GBA variant carriers, although confirmation will be required in larger samples. Screening for RBD in healthy carriers of GBA variants should be studied as a potential way to identify GBA variant carriers who will develop a synucleinopathy in the future.

4 March 2021 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
MAMaren Stolp Andersen
Maren Stolp Andersen
SBSara Bandres‐Ciga
Sara Bandres‐Ciga
RRRegina H. Reynolds
Regina H. Reynolds
JHJohn Hardy
John Hardy
MRMina Ryten
Mina Ryten
TCthe International Parkinson's Disease Genomics Consortium
the International Parkinson's Disease Genomics Consortium
Objective: Understanding how different parts of the immune system contribute to pathogenesis in Parkinson's disease is a burning challenge with important therapeutic implications. We studied enrichment of common variant heritability for Parkinson's disease stratified by immune and brain cell types.Methods: We used summary statistics from the most recent meta‐analysis of genomewide association studies in Parkinson's disease and partitioned heritability using linkage disequilibrium score regression, stratified for specific cell types, as defined by open chromatin regions. We also validated enrichment results using a polygenic risk score approach and intersected disease‐associated variants with epigenetic data and expression quantitative loci to nominate and explore a putative microglial locus.Results: We found significant enrichment of Parkinson's disease risk heritability in open chromatin regions of microglia and monocytes. Genomic annotations overlapped substantially between these 2 cell types, and only the enrichment signal for microglia remained significant in a joint model. We present evidence suggesting P2RY12, a key microglial gene and target for the antithrombotic agent clopidogrel, as the likely driver of a significant Parkinson's disease association signal on chromosome 3.Interpretation: Our results provide further support for the importance of immune mechanisms in Parkinson's disease pathogenesis, highlight microglial dysregulation as a contributing etiological factor, and nominate a targetable microglial gene candidate as a pathogenic player. Immune processes can be modulated by therapy, with potentially important clinical implications for future treatment in Parkinson's disease. ANN NEUROL 2021;89:942–951

26 April 2021 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
CBCornelis Blauwendraat
Cornelis Blauwendraat
HIHirotaka Iwaki
Hirotaka Iwaki
MMMary B. Makarious
Mary B. Makarious
SBSara Bandres‐Ciga
Sara Bandres‐Ciga
HLHampton L. Leonard
Hampton L. Leonard
T(the International Parkinson's Disease Genomics Consortium (IPDGC)
the International Parkinson's Disease Genomics Consortium (IPDGC)
Objective: Parkinson's disease (PD) is a complex neurodegenerative disorder. Men are on average ~ 1.5 times more likely to develop PD compared to women with European ancestry. Over the years, genomewide association studies (GWAS) have identified numerous genetic risk factors for PD, however, it is unclear whether genetics contribute to disease etiology in a sex‐specific manner.Methods: In an effort to study sex‐specific genetic factors associated with PD, we explored 2 large genetic datasets from the International Parkinson's Disease Genomics Consortium and the UK Biobank consisting of 13,020 male PD cases, 7,936 paternal proxy cases, 89,660 male controls, 7,947 female PD cases, 5,473 maternal proxy cases, and 90,662 female controls. We performed GWAS meta‐analyses to identify distinct patterns of genetic risk contributing to disease in male versus female PD cases.Results: In total, 19 genomewide significant regions were identified and no sex‐specific effects were observed. A high genetic correlation between the male and female PD GWAS were identified (rg = 0.877) and heritability estimates were identical between male and female PD cases (~ 20%).Interpretation: We did not detect any significant genetic differences between male or female PD cases. Our study does not support the notion that common genetic variation on the autosomes could explain the difference in prevalence of PD between males and females cases at least when considering the current sample size under study. Further studies are warranted to investigate the genetic architecture of PD explained by X and Y chromosomes and further evaluate environmental effects that could potentially contribute to PD etiology in male versus female patients. ANN NEUROL 2021;90:41–48